ArticleJMA journal2025
Health Insurance and Its Psychosocial Correlates in Patients with Advanced Lung Cancer in Japan.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Financial toxicity among patients with lung cancer: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Japan has a national health insurance system that covers at least 70% of regular medical costs and provides additional benefits for high medical costs. In addition, >60% of the population holds private health insurance to reduce financial toxicity. However, there has been a lack of real-world data on private health insurance in the oncology setting in Japan. Methods: A cross-sectional survey of health insurance was conducted at 16 hospitals in Japan between 2013 and 2016. Patients were eligible if they were newly diagnosed with clinical stage IIIB or IV lung cancer. Data collected included patients' health insurance, clinical and sociodemographic characteristics, and self-reported outcomes 3 months after diagnosis. Results: Of the 147 patients, 114 (77.6%) had private health insurance. Patients with private health insurance were significantly younger (p = 0.028), had better performance status (p = 0.029), and reported better quality of life (p = 0.017), specifically in social (p = 0.039) and emotional (p = 0.011) well-being. There were no significant associations between having private health insurance and treatment details, medical satisfaction, or financial issues. Most patients (99.3%) reported that national health insurance is necessary. A substantial proportion of patients (9.8%), particularly those without private health insurance (19.4%), reported that private health insurance is not necessary. Conclusions: Having private health insurance was associated with better quality of life, though there were no significant differences in medical care or financial issues. Our findings suggest that private health insurance plays an auxiliary role in accessing medical care for patients with advanced lung cancer in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.